WEXFORD, Pa. - Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP), a biopharmaceutical company with a market capitalization of $5.84 million, has announced the completion of its acquisition of the NexGenAI Affiliates Network platform, and the launch of a new division, Coeptis Technologies. According to InvestingPro analysis, the company appears undervalued despite its stock declining over 80% year-to-date. This move is aimed at diversifying the company's growth potential in the biotech and pharmaceutical sectors.
The NexGenAI platform, developed by NexGenAI Solutions Group, Inc., is designed to provide AI-powered marketing software and robotic process automation (RPA) capabilities. According to Coeptis, these tools are crucial for optimizing marketing strategies, enhancing customer engagement, and streamlining operations in highly regulated industries. With a current ratio of 0.4, InvestingPro data indicates the company faces some liquidity challenges, making operational efficiency improvements particularly important.
Dave Mehalick, President and CEO of Coeptis Therapeutics, emphasized the importance of integrating advanced tools like NexGenAI's platform to remain competitive and address regulatory challenges in their field. Anshuman Dash, Lead Advisory behind NexGenAI's development, remarked that the acquisition signifies a transformative step for Coeptis, aligning with its mission to innovate within highly regulated industries.
Coeptis Therapeutics, with its subsidiaries, is known for developing cell therapy platforms for various diseases, including cancer, autoimmune, and infectious diseases. It has licensed assets from Deverra Therapeutics and collaborates with entities such as VyGen-Bio and the Karolinska Institute to develop its product portfolio.
The acquisition of NexGenAI's platform is seen as a strategic move by Coeptis to leverage advanced technologies to enhance its capabilities and drive innovation within the biopharmaceutical sector. The company believes that the AI-powered solutions provided by NexGenAI will offer valuable tools for companies facing marketing challenges in competitive and highly regulated environments.
The information in this article is based on a press release statement from Coeptis Therapeutics Holdings, Inc. InvestingPro subscribers have access to additional insights, including 8 more ProTips and comprehensive financial metrics that can help evaluate the company's strategic moves and financial health.
In other recent news, Coeptis Therapeutics has witnessed a series of key developments. Shareholders of the biopharmaceutical company have approved several critical proposals, including the election of seven director nominees and the appointment of Astra Audit & Advisory, LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2023. Notably, a pivotal amendment to the company's certificate of incorporation was passed, authorizing a reverse stock split, and the issuance of up to $20.0 million of securities in connection with a Standby Equity Purchase Agreement received approval.
Coeptis Therapeutics has announced the launch of a new division, Coeptis Technologies, focused on data security, following the signing of a Letter of Intent to acquire assets from a Risk Mitigation Software (ETR:SOWGn) Company. Additionally, the company has revealed plans to acquire NexGenAI Affiliates Network, with the aim of enhancing operational efficiency and expanding its technological offerings. The company has also expanded its license agreement with Deverra Therapeutics, allowing the use of unmodified natural killer cells for pandemic preparedness and emergency use.
The company faced some financial hurdles, retracting its financial statements for several periods in 2023 and 2024 due to accounting errors. In response, Coeptis Therapeutics has appointed Astra Audit & Advisory, LLC as its new independent registered public accounting firm for the fiscal year ending December 31, 2024. Lastly, the company secured an extension to remain listed on the Nasdaq until January 15, 2025, contingent on compliance with the minimum bid price requirement. These are recent developments at Coeptis Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.